Improving systemic delivery of oncolytic virus by cellular carriers
Oncolytic virotherapy (OVT) is a promising option for cancer treatment. OVT involves selective oncolytic virus (OV) replication within cancer cells, which triggers anti-tumor responses and immunostimulation. Despite promising potential, OVT faces critical challenges, including insufficient tumor-spe...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
China Anti-Cancer Association
2024-12-01
|
| Series: | Cancer Biology & Medicine |
| Subjects: | |
| Online Access: | https://www.cancerbiomed.org/content/21/12/1104 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832098694185353216 |
|---|---|
| author | Ziyi Peng Muhammad Kalim Yong Lu |
| author_facet | Ziyi Peng Muhammad Kalim Yong Lu |
| author_sort | Ziyi Peng |
| collection | DOAJ |
| description | Oncolytic virotherapy (OVT) is a promising option for cancer treatment. OVT involves selective oncolytic virus (OV) replication within cancer cells, which triggers anti-tumor responses and immunostimulation. Despite promising potential, OVT faces critical challenges, including insufficient tumor-specific targeting, which results in limited tumor penetration and variability in therapeutic efficacy. These challenges are particularly pronounced in solid tumors with complex microenvironments and heterogeneous vascularization. A comprehensive research program is currently underway to develop and refine innovative delivery methods to address these issues to enhance OVT precision and efficacy. A principal area of investigation is the utilization of cellular carriers to enhance the delivery and distribution of OVs within tumor microenvironments, thereby optimizing immune system activation and maximizing anti-tumor effects. This review offers a comprehensive overview of the current strategies that are being used to enhance the delivery of OVs via cellular carriers with the goal of improving the clinical impact of OVT in cancer therapy. |
| format | Article |
| id | doaj-art-4908ea40c05d40a2be58c8962d176c51 |
| institution | Kabale University |
| issn | 2095-3941 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | China Anti-Cancer Association |
| record_format | Article |
| series | Cancer Biology & Medicine |
| spelling | doaj-art-4908ea40c05d40a2be58c8962d176c512025-02-05T09:57:37ZengChina Anti-Cancer AssociationCancer Biology & Medicine2095-39412024-12-0121121104111910.20892/j.issn.2095-3941.2024.0390Improving systemic delivery of oncolytic virus by cellular carriersZiyi Peng0Muhammad Kalim1Yong Lu2Houston Methodist Cancer Center/Weill Cornell Medicine, Houston, TX 77030, USAHouston Methodist Cancer Center/Weill Cornell Medicine, Houston, TX 77030, USAHouston Methodist Cancer Center/Weill Cornell Medicine, Houston, TX 77030, USAOncolytic virotherapy (OVT) is a promising option for cancer treatment. OVT involves selective oncolytic virus (OV) replication within cancer cells, which triggers anti-tumor responses and immunostimulation. Despite promising potential, OVT faces critical challenges, including insufficient tumor-specific targeting, which results in limited tumor penetration and variability in therapeutic efficacy. These challenges are particularly pronounced in solid tumors with complex microenvironments and heterogeneous vascularization. A comprehensive research program is currently underway to develop and refine innovative delivery methods to address these issues to enhance OVT precision and efficacy. A principal area of investigation is the utilization of cellular carriers to enhance the delivery and distribution of OVs within tumor microenvironments, thereby optimizing immune system activation and maximizing anti-tumor effects. This review offers a comprehensive overview of the current strategies that are being used to enhance the delivery of OVs via cellular carriers with the goal of improving the clinical impact of OVT in cancer therapy.https://www.cancerbiomed.org/content/21/12/1104oncolytic virotherapyoncolytic virussystemic deliverycellular carrierstumor-specific targeting |
| spellingShingle | Ziyi Peng Muhammad Kalim Yong Lu Improving systemic delivery of oncolytic virus by cellular carriers Cancer Biology & Medicine oncolytic virotherapy oncolytic virus systemic delivery cellular carriers tumor-specific targeting |
| title | Improving systemic delivery of oncolytic virus by cellular carriers |
| title_full | Improving systemic delivery of oncolytic virus by cellular carriers |
| title_fullStr | Improving systemic delivery of oncolytic virus by cellular carriers |
| title_full_unstemmed | Improving systemic delivery of oncolytic virus by cellular carriers |
| title_short | Improving systemic delivery of oncolytic virus by cellular carriers |
| title_sort | improving systemic delivery of oncolytic virus by cellular carriers |
| topic | oncolytic virotherapy oncolytic virus systemic delivery cellular carriers tumor-specific targeting |
| url | https://www.cancerbiomed.org/content/21/12/1104 |
| work_keys_str_mv | AT ziyipeng improvingsystemicdeliveryofoncolyticvirusbycellularcarriers AT muhammadkalim improvingsystemicdeliveryofoncolyticvirusbycellularcarriers AT yonglu improvingsystemicdeliveryofoncolyticvirusbycellularcarriers |